DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for ophthalmic herpes zoster — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOphthalmic herpes zoster maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ophthalmic herpes zoster is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nuclear receptor subfamily 3 group C member 1 (NR3C1) — NR3C1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7KW7 · 3.57 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
In 1955, four elderly patients with ophthalmic herpes zoster were treated with ACTH. The authors reported successful relief of acute pain and prevention of serious complications, but the report is a case series of four patients with no control group, no randomisation, and no quantitative survival or response rates given. The paper itself notes that herpes zoster is usually benign and self-limiting, and that innumerable remedies had previously failed to relieve pain or prevent sequelae.
A 2018 review states that herpes zoster has a lifetime risk of 33%, that herpes zoster ophthalmicus occurs in 10–20% of all zoster cases, and that ocular involvement occurs in 50% of those with ophthalmic zoster. No treatment efficacy data are provided in that abstract.
A 1984 letter on acyclovir and steroids in herpes zoster keratouveitis disagrees with withholding topical steroids, reporting that a zoster clinic had used carefully controlled topical steroids successfully for over ten years. No patient numbers, response rates, or comparative outcomes are given, and the letter does not report a controlled trial.
A 2011 nursing review describes the condition, risk factors, clinical features, diagnosis, treatment, complications, and prevention, but provides no original data on drug efficacy or patient outcomes.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1955 · 29 citations
Treatment of Herpes Zoster with ACTH
AbstractHERPES zoster is usually a benign condition followed by spontaneous recovery. However, it may have serious complications when it occurs in elderly patients or when it involves the eye. There is no specific treatment. It is in older patients with extensive involvement, and in those with herpes zoster ophthalmicus, that innumerable remedies have been tried, with no relief of the excruciating pain in the acute stage of the disease and no prevention of serious complications and sequelae. For this reason, it seemed worth while to report on the successful treatment of herpes zoster with ACTH in 4 such patients. Other . . .
Canadian Medical Association Journal · 2018 · 9 citations · open access
Herpes zoster ophthalmicus
AbstractHerpes zoster has a lifetime risk of 33%, and older adults and patients who are immunocompromised are at higher risk.[1][1] Herpes zoster ophthalmicus occurs in 10% to 20% of cases of herpes zoster, with ocular involvement in 50% of those of herpes zoster ophthalmicus.[1][1] Lesions on the tip, side
British Journal of Ophthalmology · 1984 · 9 citations · open access
Acyclovir and steroids in herpes zoster keratouveitis.
AbstractAcyclovir and steroids in herpes zoster keratouveitis SIR, We read McGill and Chapman's article' with much interest. While we agree with them regarding steroid dependency of many of the inflammatory ocular complica- tions of zoster with the attendant difficulty of withdrawal, and that there are significant complications of long term topical steroids, we would not agree to withholding these valuable drugs. In the Zoster Clinic carefully controlled topical steroids have been used successfully in the inflam- matory complications of ophthalmic zoster for over 10 years.
Managing the care of patients with herpes zoster ophthalmicus
AbstractThe herpes zoster virus is a common neurocutaneous infection. When the eye is involved, the virus is referred to as herpes zoster ophthalmicus. This article discusses the role of the nurse in managing the care of patients with herpes zoster ophthalmicus. It provides an overview of the condition and its associated pathophysiology. The article examines risk factors, clinical features, diagnosis, treatment, complications and prevention. It also discusses the care required to support patients during their treatment and subsequent rehabilitation.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
